S&P 500   4,632.24 (-0.49%)
DOW   34,921.34 (-0.61%)
QQQ   400.14 (+0.11%)
AAPL   164.06 (+2.38%)
MSFT   337.17 (+0.16%)
FB   334.79 (-0.96%)
GOOGL   2,903.78 (-0.23%)
AMZN   3,570.66 (+0.26%)
TSLA   1,162.67 (+2.26%)
NVDA   331.56 (-0.66%)
BABA   129.75 (-1.41%)
NIO   40.71 (+0.62%)
CGC   10.83 (-2.08%)
AMD   163.54 (+1.01%)
GE   95.99 (-2.45%)
MU   86.17 (+0.03%)
T   23.04 (-3.56%)
F   19.49 (-0.92%)
DIS   145.41 (-1.62%)
ACB   6.40 (-0.62%)
AMC   35.50 (-3.64%)
PFE   53.50 (+2.10%)
BA   196.04 (-1.24%)
S&P 500   4,632.24 (-0.49%)
DOW   34,921.34 (-0.61%)
QQQ   400.14 (+0.11%)
AAPL   164.06 (+2.38%)
MSFT   337.17 (+0.16%)
FB   334.79 (-0.96%)
GOOGL   2,903.78 (-0.23%)
AMZN   3,570.66 (+0.26%)
TSLA   1,162.67 (+2.26%)
NVDA   331.56 (-0.66%)
BABA   129.75 (-1.41%)
NIO   40.71 (+0.62%)
CGC   10.83 (-2.08%)
AMD   163.54 (+1.01%)
GE   95.99 (-2.45%)
MU   86.17 (+0.03%)
T   23.04 (-3.56%)
F   19.49 (-0.92%)
DIS   145.41 (-1.62%)
ACB   6.40 (-0.62%)
AMC   35.50 (-3.64%)
PFE   53.50 (+2.10%)
BA   196.04 (-1.24%)
S&P 500   4,632.24 (-0.49%)
DOW   34,921.34 (-0.61%)
QQQ   400.14 (+0.11%)
AAPL   164.06 (+2.38%)
MSFT   337.17 (+0.16%)
FB   334.79 (-0.96%)
GOOGL   2,903.78 (-0.23%)
AMZN   3,570.66 (+0.26%)
TSLA   1,162.67 (+2.26%)
NVDA   331.56 (-0.66%)
BABA   129.75 (-1.41%)
NIO   40.71 (+0.62%)
CGC   10.83 (-2.08%)
AMD   163.54 (+1.01%)
GE   95.99 (-2.45%)
MU   86.17 (+0.03%)
T   23.04 (-3.56%)
F   19.49 (-0.92%)
DIS   145.41 (-1.62%)
ACB   6.40 (-0.62%)
AMC   35.50 (-3.64%)
PFE   53.50 (+2.10%)
BA   196.04 (-1.24%)
S&P 500   4,632.24 (-0.49%)
DOW   34,921.34 (-0.61%)
QQQ   400.14 (+0.11%)
AAPL   164.06 (+2.38%)
MSFT   337.17 (+0.16%)
FB   334.79 (-0.96%)
GOOGL   2,903.78 (-0.23%)
AMZN   3,570.66 (+0.26%)
TSLA   1,162.67 (+2.26%)
NVDA   331.56 (-0.66%)
BABA   129.75 (-1.41%)
NIO   40.71 (+0.62%)
CGC   10.83 (-2.08%)
AMD   163.54 (+1.01%)
GE   95.99 (-2.45%)
MU   86.17 (+0.03%)
T   23.04 (-3.56%)
F   19.49 (-0.92%)
DIS   145.41 (-1.62%)
ACB   6.40 (-0.62%)
AMC   35.50 (-3.64%)
PFE   53.50 (+2.10%)
BA   196.04 (-1.24%)
NYSE:PFX

PhenixFIN Stock Forecast, Price & News

$41.40
-0.60 (-1.43%)
(As of 11/30/2021 03:45 AM ET)
Add
Compare
Today's Range
$41.40
$41.40
50-Day Range
$41.40
$43.35
52-Week Range
$24.70
$44.00
Volume
9,582 shs
Average Volume
7,273 shs
Market Capitalization
$104.20 million
P/E Ratio
11.56
Dividend Yield
N/A
Beta
1.67
30 days | 90 days | 365 days | Advanced Chart
Receive PFX News and Ratings via Email

Sign-up to receive the latest news and ratings for PhenixFIN and its competitors with MarketBeat's FREE daily newsletter.


About PhenixFIN

Medley Capital Corporation is a non-diversified closed-end management investment company. The Company's investment objective is to generate current income and capital appreciation by lending directly to privately-held middle market companies, primarily through directly originated transactions to help these companies expand their business, refinance and make acquisitions. Its investment portfolio includes senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may invest up to 100% of its assets in securities acquired directly from issuers in privately negotiated transactions.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Securities and Commodity Exchanges
Sub-Industry
N/A
Sector
Finance
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$21.52 million
Cash Flow
$0.01 per share
Book Value
$55.30 per share

Profitability

Net Income
$-65.81 million
Pretax Margin
18.35%

Debt

Price-To-Earnings

Miscellaneous

Free Float
2,223,000
Market Cap
$104.20 million
Optionable
Not Optionable

Company Calendar

Last Earnings
8/10/2021
Today
11/30/2021
Next Earnings (Estimated)
12/10/2021
Fiscal Year End
9/30/2022

MarketRank

Overall MarketRank

1.73 out of 5 stars

Finance Sector

926th out of 1,335 stocks

Securities And Commodity Exchanges Industry

1st out of 1 stocks

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












PhenixFIN (NYSE:PFX) Frequently Asked Questions

Is PhenixFIN a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhenixFIN in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PhenixFIN stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFX, but not buy additional shares or sell existing shares.
View analyst ratings for PhenixFIN
or view top-rated stocks.

How has PhenixFIN's stock been impacted by Coronavirus?

PhenixFIN's stock was trading at $18.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PFX shares have increased by 118.8% and is now trading at $41.40.
View which stocks have been most impacted by COVID-19
.

When is PhenixFIN's next earnings date?

PhenixFIN is scheduled to release its next quarterly earnings announcement on Friday, December 10th 2021.
View our earnings forecast for PhenixFIN
.

How were PhenixFIN's earnings last quarter?

PhenixFIN Co. (NYSE:PFX) issued its earnings results on Tuesday, August, 10th. The company reported $2.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $2.57. The company earned $8.68 million during the quarter, compared to analyst estimates of $2.52 million. PhenixFIN had a net margin of 29.64% and a trailing twelve-month return on equity of 11.01%.
View PhenixFIN's earnings history
.

Who are PhenixFIN's key executives?

PhenixFIN's management team includes the following people:
  • David Aaron Lorber, Chief Executive Officer
  • Ellida McMillan, Chief Financial Officer
  • John D. Fredericks, Chief Compliance Officer
  • Michael Vitale, Senior Vice President & Controller
  • Howard Liao, Chief Investment Officer & Senior MD

Who are some of PhenixFIN's key competitors?

What other stocks do shareholders of PhenixFIN own?

What is PhenixFIN's stock symbol?

PhenixFIN trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFX."

Who are PhenixFIN's major shareholders?

PhenixFIN's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Morgan Stanley (2.83%), Adalta Capital Management LLC (0.76%), Millennium Management LLC (0.36%), O Shaughnessy Asset Management LLC (0.11%) and UBS Group AG (0.03%).
View institutional ownership trends for PhenixFIN
.

Which institutional investors are selling PhenixFIN stock?

PFX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, and UBS Group AG.
View insider buying and selling activity for PhenixFIN
or view top insider-selling stocks.

Which institutional investors are buying PhenixFIN stock?

PFX stock was acquired by a variety of institutional investors in the last quarter, including Adalta Capital Management LLC, Morgan Stanley, and O Shaughnessy Asset Management LLC.
View insider buying and selling activity for PhenixFIN
or or view top insider-buying stocks.

How do I buy shares of PhenixFIN?

Shares of PFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PhenixFIN's stock price today?

One share of PFX stock can currently be purchased for approximately $41.40.

How much money does PhenixFIN make?

PhenixFIN has a market capitalization of $104.20 million and generates $21.52 million in revenue each year. The company earns $-65.81 million in net income (profit) each year or $3.58 on an earnings per share basis.

What is PhenixFIN's official website?

The official website for PhenixFIN is www.medleycapitalcorp.com.

Where are PhenixFIN's headquarters?

How can I contact PhenixFIN?

PhenixFIN's mailing address is 280 PARK AVENUE 6TH FLOOR EAST, NEW YORK NY, 10017. The company can be reached via phone at (212) 859-0390, via email at [email protected], or via fax at 212-759-0091.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.